Source: Annual Congress 2006 - Common and differing aspects of acute and chronic lung injury
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. S. Lebedeva, L. N. Danilov, A. S. Simbirtsev, I. V. Dvorakovskaya (St. Petersburg, Russian Federation). Approach to pathogenetic treatment of experimental pulmonary fibrosis. Eur Respir J 2006; 28: Suppl. 50, 3723

Member's Comments

No comment yet.

Related content which might interest you: Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Approach to diagnosis of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 Angiogenesis in experimental pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 The pathogenesis of pulmonary fibrosis: a moving target Source: Eur Respir J 2013; 41: 1207-1218 Year: 2013 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Idiopathic pulmonary fibrosis: present understanding and future options Source: Eur Respir Rev 2011; 20: 132-133 Year: 2011 PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip Source: ERS Lung Science Conference 2021 Year: 2021 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012 Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015